Double blind comparison between iohexol and metrizoate in phlebography of the lower limb.
A new, non-ionic low osmolar contrast medium, iohexol 240 mg I/ml, has been tested in a randomized double blind parallel investigation versus meglumine-Ca metrizoate 200 mg I/ml. The study was performed to evaluate the suitability of the contrast medium in phlebography. No post-phlebographic complications were seen in the 24 patients examined with iohexol 240 mg I/ml or in 8 patients examined with iohexol 300 mg I/ml. In the 19 patients examined with metrizoate 200 mg I/ml, 7 had a post-phlebographic thrombotic complication (37%). The radiographic image quality was not significantly different between the two contrast media, neither were the immediate side effects during contrast injections. It has thus been shown that iohexol is a suitable contrast medium in phlebography of the lower limb and that it is preferable to conventional contrast media.
D000328:Adult; D000368:Aged; D003287:Contrast Media / Q000633:toxicity; D004311:Double-Blind Method; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D007463:Iodobenzoates; D007472:Iohexol; D007866:Leg / Q000098:blood supply / Q000000981:diagnostic imaging*; D008297:Male; D008794:Metrizoic Acid / Q000633:toxicity; D008875:Middle Aged; D010690:Phlebography / Q000009:adverse effects; D011897:Random Allocation; D013924:Thrombophlebitis / Q000000981:diagnostic imaging*; D014283:Triiodobenzoic Acids / Q000633:toxicity
D003287:Contrast Media; D007463:Iodobenzoates; D014283:Triiodobenzoic Acids; D007472:Iohexol; D008794:Metrizoic Acid